News and press releases - Cantargia

* (R) = Regulatory press releases

14 Oct, 2021

(R) Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer

30 Sep, 2021

(R) Cantargia’s extensive patent protection for IL1RAP-targeting cancer therapy remains in force after concluded opposition

29 Sep, 2021

(R) Cantargia receives regulatory approval to start TRIFOUR study in triple negative breast cancer

22 Sep, 2021

(R) Cantargia: FDA grants Orphan Drug Designation to nadunolimab for treatment of pancreatic cancer

16 Sep, 2021

(R) Cantargia presents positive interim data for nadunolimab combination therapy at ESMO Congress

12 Sep, 2021

(R) Cantargia: New positive interim results on nadunolimab combination therapy in NSCLC published in abstract for the annual ESMO Congress

10 Sep, 2021

(R) Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy

10 Sep, 2021

(R) Cantargia completes patient recruitment to the phase IIa pancreatic cancer extension cohort in the CANFOUR study

06 Sep, 2021

(R) Cantargia expands nadunolimab development in non-squamous NSCLC

01 Sep, 2021

(R) Cantargia strengthens the company management team

Older press releases >>

CEO interview, Redeye, (In Swedish) - 2021-08-31

Redeye

CEO interview, Di TV (In Swedish) - 2021-05-26

Di TV

CEO presentation AGM (In Swedish) - 2021-05-26

Bio Stock

CEO interview, Redeye, (In Swedish) - 2021-05-24

Redeye

CEO interview, Redeye, (In Swedish) - 2021-05-11

Redeye

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CEO interview, direct share issue, Redeye (In Swedish) - 2020-12-16

Redeye

CEO interview, direct share issue, Di TV (In Swedish) - 2020-12-16

Di TV

CEO interview, EFN (In Swedish) - 2020-10-16

EFN

CEO interview, Penser Bank Cancer Research Day (In Swedish) - 2020-10-07

Penser Bank

Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31

Affärstidningen Näringsliv

Presentation at ASCO 2019, follow up articles and interviews - 2019-07-02

ASCO

Cantargia interview at EFN after ASCO - 2019-06-17

EFN

CEO interview, Edison, London - 2019-02-26

Edison TV

CEO interview, EFN, Lund (In Swedish) - 2018-11-22

EFN

Interview around CAN04 clinical results, Redeye, Stockholm (In Swedish) - 2018-10-23

Redeye

Listing ceremony for Cantargia on Nasdaq Stockholm Main Market - 2018-09-25

Nasdaq

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), EFN, Stockholm (In Swedish) - 2018-09-25

EFN

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), Ditv, Stockholm (In Swedish) - 2018-09-25

Di

CEO interview, Redeye, Stockholm (In Swedish) 2018-09-06

Redeye

CEO interview, BioStock Live, Stockholm (In Swedish) -2018-08-29

Direkt Studios

Småbolagspanelen: Om framtidens cancerbehandlingar, Småbolagsdagen, Stockholm (in Swedish) 2018-06-11

Aktiespararna

CEO interview BioStock Live, Stockholm (In Swedish) -2018-03-20

Direkt Studios

CEO-interview 2017-12-12

Aktiespararna

Interview with Cantargia's CEO Göran Forsberg after the presentation at BioStock Live i Stockholm - 2017-12-04

Direkt Studios

CEO-interview - 2017-11-29

Finwire.tv

Video, interview Göran Forsberg, President Cantargia, Sedermera-dagen, Lund - 2016-03-16

Finwire.tv

© Copyright 2021 · Cantargia AB